ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

RMJ. 2025; 50(3): 584-587


Assessing the neutrophil-to-lymphocyte ratio as a biomarker for predicting the severity of coronary artery disease using Gensini Score

Muhammad Noor Ul Amin, Asad Mehmood Raja, Muhammad Javaid Asad, Abida Arshad, Ghazala Kaukab Raja, Pakeeza Arzoo Shaiq.



Abstract
Download PDF Post

Objective: To evaluate the predictive value of neutrophil-to-lymphocyte ratio in assessing the severity of coronary artery disease, as determined by the Gensini score.
Methodology: This retrospective study included 1,020 patients who underwent coronary angiography at the Rawalpindi Institute of Cardiology, Pakistan. The severity of coronary artery disease was classified using the Gensini scoring system. The association between neutrophil-to-lymphocyte ratio and disease severity was analyzed through univariate and multivariate logistic regression analysis. Receiver operating characteristic curve analysis was performed to evaluate its predictive ability.
Results: Mean age of participants was 58.3±10.48 years, with 69.59% being male. Patients with very severe coronary artery disease had significantly higher neutrophil-to-lymphocyte ratios (mean = 5.93±10.94) compared to those without disease (mean = 2.77±3.44; p

Key words: Neutrophil to lymphocyte ratio, Gensini Score, biomarker.







Bibliomed Article Statistics

26
25
25
12
8
R
E
A
D
S

54

36

34

14

3
D
O
W
N
L
O
A
D
S
0809101112
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.